Sphingotec

14/05/2026

The AFIAS sphingotest® penKid® (IVDR-marked) supports the diagnosis of acute kidney injury (AKI) in adult patients with sepsis or septic shock, providing a rapid turnaround time optimized for time-critical clinical settings. PenKid is now commercially available for routine clinical use in the European market through the network of authorized partners.

New to penKid? Contact Boditech Med marketing@boditech.co.kr to learn about clinical applications.

12/05/2026

📣 The scientific community has been asking — and we’ve listened.

SphingoTec is expanding access to the kidney function biomarker Proenkephalin 119-159 (penKid) with the ELISA sphingotest® penKid®, enabling research teams worldwide to measure penKid using standard laboratory systems.

Designed to support research teams advancing kidney function science.

Order online: https://www.sphingotec.eu/product/ELISA-sphingotest-penKid

ELISA sphingotest® penKid® enables widespread measurement of the kidney function biomarker Proenkephalin 119-159 (penKid) using standard photometers.

07/05/2026

Two complementary solutions for Proenkephalin A 119-159 (penKid) measurement: AFIAS sphingotest® penKid® and ELISA sphingotest® penKid®.

AFIAS sphingotest® penKid® (Boditech Med):
• IVDR-marked for clinical routine use
• Rapid results (15 min) optimized for acute care
• Available through certified distributors

ELISA sphingotest® penKid® (SphingoTec):
• Research Use Only
• Laboratory solution for high-throughput studies
• Standard photometer compatible

Same biomarker. Different applications.

04/05/2026

Researchers can now order the ELISA sphingotest® penKid® directly from the SphingoTec shop.
Providing accessibility, precision, and validated performance, this ELISA supports studies into kidney function and biomarker applications across research settings.
→ Learn more and request your kit here: https://www.sphingotec.eu/store

30/04/2026

PenKid in clinical routine – powered by SphingoTec and Boditech Med partnership.
SphingoTec discovered and validated Proenkephalin 119-159 (penKid) as kidney function biomarker.
Boditech developed AFIAS sphingotest® penKid® –IVDR-certified and commercially available in Europe.
Interested in routine penKid implementation?
Contact us for:
• Clinical evidence and reference data
• Implementation support
• Partnership opportunities
Advancing kidney diagnostics together. https://www.sphingotec.eu/contact

28/04/2026

SphingoTec GmbH announces the launch of the ELISA sphingotest® penKid®, a new assay designed to make testing of its proprietary biomarker broadly accessible to research laboratories and pharmaceutical partners. Providing ease-of-use and precision, the test facilitates large-scale investigations of human kidney function in both acute and broader clinical research contexts.
Read more in the press release https://www.sphingotec.eu/sphingotec-introduces-elisa-sphingotest-penkid-to-enable-broad-kidney-biomarker-testing-for-research-applications

13/04/2026

We are proud to contribute to the forward-looking conversations shaping the future of kidney care and clinical trial innovation!
At the KDCT 2026 Workshop in Washington, DC, SphingoTec’s Managing Director and Chief Medical Officer, Dr. Florian Uhle, took the stage during “Session 9A: AKI 3 — KDCT AKI Trial Design Studio: AI innovations in clinical trials design and analysis”, alongside global experts from academia, regulatory bodies, and industry. Managing Director and CEO Deborah Bergmann also represented SphingoTec in discussions with industry leaders, exploring opportunities to advance kidney focused diagnostics and clinical development.
This inspiring session explored how AI-driven trial design, predictive enrichment, and adaptive simulation frameworks can reduce complexity and uncover deeper causal insights into acute kidney injury (AKI) research.
We are honored to be part of the key discussions driving progress in kidney diagnostics and clinical trial methodology — especially as our biomarker penKid continues to shed light on previously unseen dimensions of kidney function and patient outcomes.
📍 More about the program: https://www.kdctmeeting.com/scientific-program-2026

25/03/2026

Freshly published in Critical Care (Springer Nature): When creatinine looks “normal”, penKid tells a different story.
In patients with sepsis or septic shock, early recognition of kidney deterioration is critical. Yet many at‑risk patients remain undetected because their serum creatinine (sCr) levels still appear normal.
A newly released patient‑level meta‑analysis now provides robust clinical evidence that proenkephalin A 119–159 (penKid) offers predictive value beyond sCr for assessing kidney function and prognosis.
Drawing on data from over 2,200 patients across four independent studies, the analysis demonstrated:
✅ penKid predicts worsening renal function (WRF) and 28 day mortality, even when sCr remains within the normal range.
✅ Combining penKid with sCr improves risk stratification and supports timely clinical decisions in sepsis management.
These findings shed light on a clinically underserved group of patients—those who already experience functional deterioration despite normal creatinine values.
penKid helps close this diagnostic gap, supporting earlier and more precise patient care.
👉 Read the full publication:
Clinical utility of proenkephalin A 119–159 for prediction of worsening renal function and prognosis in patients with sepsis – results of a patient-level meta-analysis | Critical Care (Springer Nature) https://link.springer.com/article/10.1186/s13054-026-05947-5?_gl=1*1ptll6f*_up*MQ..*_gs*MQ..&gclid=Cj0KCQjw7IjOBhDyARIsAFzrWQwvkf1PKYxNfx_pD0MWgBrVUdMybvdKf5ZA4-QcqKKl8I89zta0thYaAiyrEALw_wcB #

Proenkephalin A 119–159 (penKid) is a functional kidney biomarker inversely correlating with the glomerular filtration rate. We conducted a patient-l

06/03/2026

🚀 SphingoTec is excited to join BIO-Europe this year, Europe’s leading partnering event for the global biopharma community.

Our focus: enabling out-licensing of our novel IVD biomarkers and exploring strategic pharma collaborations to bring precision diagnostics to patients worldwide.

👥 Representing SphingoTec:
• Deborah Bergmann, CEO & Managing Partner
• Nicole Witzmann, CFO

You can request a partnering meeting with us via the official BIO-Europe partnering platform or write us to schedule 1:1 meetings during the event. We look forward to exchanging on co-development, companion diagnostics, and out-licensing opportunities.

📅 March 23-25, 2026 | Feira Internacional de Lisboa

12/12/2025

A new publication strengthens the clinical evidence for proenkephalin A 119-159 ( ) in chronic kidney disease (CKD), opening perspectives beyond the acute kidney injury setting.
A recently published study analyzed more than 4,700 individuals with available penKid values from three independent cohorts, focusing specifically on CKD with a median follow-up of around 8.7 years. These longitudinal data add to the evidence base of penKid and support its potential in future application beyond the AKI indication.

Highlights
• penKid levels are strongly, independently, and inversely associated with renal function across the full range of eGFR categories.
• Higher baseline penKid concentrations predict adverse renal outcomes in CKD patients and provide added value to established clinical variables.

Impact
• Implementing penKid as a diagnostic tool could significantly enhance prognostication and monitoring of CKD.
• penKid levels support risk stratification and guide individualized treatment approaches in patients with CKD.
• Integration of penKid into existing risk tools or future algorithms might improve accuracy and could drive broader adoption in nephrology practice.

Read more https://academic.oup.com/ndt/advance-article-abstract/doi/10.1093/ndt/gfaf214/8292656?redirectedFrom=fulltext&login=false

ABSTRACTBackground and hypothesis. The endogenous opioid proenkephalin (PENK) has been identified as an independent risk marker for acute cardiovascular di

05/12/2025

penKid takes the stage again at !

Following the strong presence of Proenkephalin A 119–159 ( ) at the poster sessions this week, the biomarker has now taken center stage in the plenary talks of DIVI25.

During the session Beendigung des Nierenersatzes: Praxis und Evidenz (Discontinuation of Renal Replacement Therapy: Practice and Evidence), penKid was highlighted as a promising biomarker with potential relevance for guiding the discontinuation of renal replacement therapy.

This recognition in a high-level clinical discussion reinforces the growing scientific and clinical interest in penKid as a decision-support marker for acute kidney care — an area where conventional markers still leave a significant unmet medical need.

For those interested in the body of evidence supporting this emerging application, our whitepaper provides a detailed overview of the current research and clinical data on penKid in acute kidney injury and for discontinuation of renal replacement therapy.
📄 Read more here: https://www.sphingotec.eu/resources